InvestorsHub Logo
Followers 58
Posts 10144
Boards Moderated 1
Alias Born 09/21/2016

Re: WolfofMia post# 399735

Tuesday, 01/24/2023 10:53:38 AM

Tuesday, January 24, 2023 10:53:38 AM

Post# of 462250

“I’m very excited about these 1-year data,” said Remi Barbier, President & CEO. “They add strength and determination to our goal of helping people fight Alzheimer’s disease. Simufilam is an innovative drug candidate that we are developing methodically, one study at a time, and this open-label safety study served its purpose. Next up in 2023 are top-line clinical results of our Cognition Maintenance Study, which is a randomized, controlled trial.”



Not impressed, with this non placebo controlled trial.

WolfofMia

Imagine if we had this data? We would be in penny land!

https://finance.yahoo.com/news/cassava-sciences-announces-positive-top-141500143.html

Brings to mind something Shakespeare once said about ..."Faint Praise...".
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News